Indivior (NASDAQ:INDV) Sets New 52-Week High – Should You Buy?

Indivior PLC (NASDAQ:INDV)’s share price reached a new 52-week high on Wednesday . The stock traded as high as $32.45 and last traded at $32.5030, with a volume of 371 shares trading hands. The stock had previously closed at $32.26.

Analyst Ratings Changes

Several brokerages recently issued reports on INDV. Piper Sandler reissued an “overweight” rating and issued a $41.00 price objective (up previously from $27.00) on shares of Indivior in a research note on Friday, October 31st. Jefferies Financial Group initiated coverage on Indivior in a research note on Tuesday, July 22nd. They set a “buy” rating and a $20.00 price target on the stock. Craig Hallum reaffirmed a “buy” rating and issued a $41.00 price objective on shares of Indivior in a research note on Friday, October 31st. HC Wainwright increased their target price on shares of Indivior from $28.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Finally, Northland Securities set a $40.00 price target on shares of Indivior in a report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $32.17.

Indivior Stock Performance

The business has a 50 day moving average of $25.86 and a two-hundred day moving average of $20.01. The stock has a market capitalization of $4.38 billion, a PE ratio of 51.25 and a beta of 0.68.

Indivior (NASDAQ:INDV) last announced its earnings results on Thursday, October 30th. The company reported $0.72 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.34. Indivior had a net margin of 6.65% and a negative return on equity of 86.28%. The business had revenue of $314.00 million during the quarter, compared to the consensus estimate of $257.66 million. Indivior has set its FY 2025 guidance at EPS. On average, equities analysts expect that Indivior PLC will post 1.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Indivior

Several institutional investors and hedge funds have recently bought and sold shares of INDV. Oaktree Capital Management LP lifted its holdings in shares of Indivior by 2,241.6% during the 3rd quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock valued at $6,215,206,000 after purchasing an additional 246,776,273 shares during the last quarter. Divisadero Street Capital Management LP increased its position in Indivior by 2,372.5% during the 3rd quarter. Divisadero Street Capital Management LP now owns 3,362,605 shares of the company’s stock valued at $81,072,000 after buying an additional 3,226,605 shares in the last quarter. Newtyn Management LLC raised its stake in Indivior by 61.1% in the third quarter. Newtyn Management LLC now owns 4,200,000 shares of the company’s stock valued at $101,262,000 after buying an additional 1,592,982 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Indivior by 1,122.6% in the second quarter. Geode Capital Management LLC now owns 1,576,915 shares of the company’s stock worth $23,244,000 after acquiring an additional 1,447,939 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Indivior in the third quarter worth about $33,496,000. 60.33% of the stock is owned by hedge funds and other institutional investors.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.